JH
Jane Harness
Senior Vice President, Clinical Sciences and Portfolio Management
Innovation PharmaceuticalsInnovation Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Brilacidin (IV) | Acute Bacterial Skin and Skin Structure Infection (ABSSSI) | Phase 2b |
| Brilacidin (Oral Rinse) | Oral Mucositis in Head & Neck Cancer (Prevention) | Phase 2 |
| Brilacidin (Enema) | Ulcerative Proctitis/Proctosigmoiditis (IBD) | Phase 2 |
| Brilacidin | Hard-to-Treat Fungal Diseases | Preclinical |
| BEAMED | Image-Guided Surgical Laser (Oncology, Neurology) | Discovery |